ESR1 and breast carcinoma: However, erucin potentiates the anticancer activity of 4-hydroxytamoxifen in estrogen receptor-positive breast cancer cell lines [26] and, in combination with lapatinib, seems to overcome drug resistance in the same cells [27,28].